Clinical trial
Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With…
NCT00073723 · Celgene Corporation, Industry · Completed
Key facts
| NCT number | NCT00073723 |
|---|---|
| Title | Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer |
| Official title | An Open-label, Phase I/II Trial of ABI-007 (A Cremophor EL-Free, Protein Stabilized, Nanoparticle, Paclitaxel) Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer |
| Lead sponsor | Celgene Corporation, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | ABI-007 |
| Enrollment | 75 |
| Start date | Dec 1, 2003 |
| Completion | Jan 1, 2007 |
| First posted | Dec 5, 2003 |
| Last update posted | Dec 15, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: